Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAMXG1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	27	AUG 11	Derwent World Patents Index(R) web-based training during August
NEWS	28	AUG 11	STN AnaVist workshops to be held in North America
NEWS	29	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS	30	AUG 30	CASREACT - Enhanced with displayable reaction conditions

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items

```
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:15:29 ON 07 SEP 2005

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY   SESSION
FULL ESTIMATED COST                                     0.21      0.21

FILE 'REGISTRY' ENTERED AT 11:15:39 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 SEP 2005  HIGHEST RN 862534-94-9
DICTIONARY FILE UPDATES:   6 SEP 2005  HIGHEST RN 862534-94-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Documents and Settings\mgraffeo\My Documents\Critical
Data\10533077\compound.str
```





chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
8-10 10-11 10-12 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
5-7 6-9 7-8 8-9 8-10 10-11 10-12
exact bonds :
12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L1 STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 11:15:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2552 TO ITERATE

100.0% PROCESSED 2552 ITERATIONS 2382 ANSWERS
SEARCH TIME: 00.00.01

L2 2382 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 11:16:03 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

```
FILE COVERS 1907 - 7 Sep 2005  VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005  (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l2
L3         4437 L2

=> s l3 and  (fenoctime or "oleic acid" or catechin or scopadulciol or pentagalloyl
or bufalin or bafilomycin or concanamycin) and ige and allerg and (asthma or
urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)
AND IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l3 and (fenoctime or "oleic acid" or catechin or scopadulciol or pentagalloyl
or bufalin or bafilomycin or concanamycin) and ige and allerg and (asthma or
urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)
             0 FENOCTIME
         61237 "OLEIC"
       4030191 "ACID"
         52124 "OLEIC ACID"
                 ("OLEIC"(W)"ACID")
          7807 CATECHIN
            19 SCOPADULCIOL
            74 PENTAGALLOYL
           333 BUFALIN
          1157 BAFILOMYCIN
           301 CONCANAMYCIN
         19865 IGE
             5 ALLERG
         28236 ASTHMA
          2027 URTICARIA
         10736 ANAPHYLAXIS
          5122 RHINITIS
           523 BRONCHIECTASIS
         15489 DERMATITIS
         15736 MALARIA
L4           0 L3 AND (FENOCTIME OR "OLEIC ACID" OR CATECHIN OR SCOPADULCIOL
               OR PENTAGALLOYL OR BUFALIN OR BAFILOMYCIN OR CONCANAMYCIN) AND
               IGE AND ALLERG AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINIT
               IS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> s l3 and and ige and allerg and (asthma or urticaria or anaphylaxis or rhinitis
or bronchiectasis or dermatitis or malaria)
MISSING TERM 'AND AND'
The search profile that was entered contains a logical
operator followed immediately by another operator.

=> s l3 and ige and allerg and (asthma or urticaria or anaphylaxis or rhinitis or
bronchiectasis or dermatitis or malaria)
         19865 IGE
             5 ALLERG
         28236 ASTHMA
          2027 URTICARIA
         10736 ANAPHYLAXIS
          5122 RHINITIS
           523 BRONCHIECTASIS
         15489 DERMATITIS
         15736 MALARIA
L5           0 L3 AND IGE AND ALLERG AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS
```

OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> s l3 and ige and allerg? and (asthma or urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)

	19865	IGE
	62330	ALLERG?
	28236	ASTHMA
	2027	URTICARIA
	10736	ANAPHYLAXIS
	5122	RHINITIS
	523	BRONCHIECTASIS
	15489	DERMATITIS
	15736	MALARIA
L6	4	L3 AND IGE AND ALLERG? AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> s l3 and (fenoctime or "oleic acid" or catechin or scopadulciol or pentagalloyl or bufalin or bafilomycin or concanamycin) and ige and allerg? and (asthma or urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)

	0	FENOCTIME
	61237	"OLEIC"
	4030191	"ACID"
	52124	"OLEIC ACID" ("OLEIC"(W)"ACID")
	7807	CATECHIN
	19	SCOPADULCIOL
	74	PENTAGALLOYL
	333	BUFALIN
	1157	BAFILOMYCIN
	301	CONCANAMYCIN
	19865	IGE
	62330	ALLERG?
	28236	ASTHMA
	2027	URTICARIA
	10736	ANAPHYLAXIS
	5122	RHINITIS
	523	BRONCHIECTASIS
	15489	DERMATITIS
	15736	MALARIA
L7	1	L3 AND (FENOCTIME OR "OLEIC ACID" OR CATECHIN OR SCOPADULCIOL OR PENTAGALLOYL OR BUFALIN OR BAFILOMYCIN OR CONCANAMYCIN) AND IGE AND ALLERG? AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> d bib abs

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS,				

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI KR 2002-67653 A 20021102
KR 2003-75511 A 20031028
AB The invention discloses a composition for inhibiting the secretion of an **IgE**-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, **oleic acid**, **catechin**, **scopadulciol**, **pentagalloyl** glucose, **bufalin**, and macrolide antibiotic **bafilomycin** and **concanamycin**, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various **allergic** diseases and **malaria**, which are caused by the **IgE**-dependent histamine-releasing factor.

=> s l6
19865 IGE
62330 ALLERG?
28236 ASTHMA
2027 URTICARIA
10736 ANAPHYLAXIS
5122 RHINITIS
523 BRONCHIECTASIS
15489 DERMATITIS
15736 MALARIA
L8 4 L3 AND IGE AND ALLERG? AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> d 1-4 bib abs hitstr

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:834661 CAPLUS
DN 142:348646
TI Recurrent **anaphylaxis** linked to pantoprazole
AU Kollmeier, Alexa P.; Eddleston, Jane; Zuraw, Bruce L.; Christiansen, Sandra C.
CS Department of Asthma, Allergy and Immunol., Scripps Clin., La Jolla, CA, 92037, USA
SO Journal of Allergy and Clinical Immunology (2004), 114(4), 975-977
CODEN: JACIBY; ISSN: 0091-6749
PB Elsevier Inc.
DT Journal
LA English
AB The case of a 47-yr-old man with recurrent **anaphylaxis** induced by pantoprazole, a benzimidazole proton pump inhibitor, is presented. In this patient, the pos. skin test response and increased tryptase level are consistent with prior case reports of proton pump inhibitor **anaphylaxis** and suggest an immediate hypersensitivity mechanism. Although mutations in the CYP2C19 gene were not identified, the timing of anaphylactic events invokes the possible involvement of modifying pharmacogenetic factors, variations in relative levels of drug-specific **IgE**, or both.
IT **102625-70-7**, Pantoprazole **138786-67-1**, Protonix
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(recurrent **anaphylaxis** linked to pantoprazole)

RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 138786-67-1 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI KR 2002-67653	A	20021102		
KR 2003-75511	A	20031028		

AB The invention discloses a composition for inhibiting the secretion of an **IgE**-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound

having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various **allergic** diseases and **malaria**, which are caused by the **IgE** -dependent histamine-releasing factor.

IT **73590-58-6**, Omeprazole **102625-70-7**, Pantoprazole **103577-45-3**, Lansoprazole **117976-89-3**, Rabeprazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazolic compound with proton pump inhibitor activity for preventing secretion of **IgE**-dependent histamine releasing factor)

RN 73590-58-6 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:223222 CAPLUS
DN 137:257592
TI T-cell reactions to drugs in distinct clinical manifestations of drug **allergy**
AU Neukomm, Corinne B.; Yawalkar, Nikhil; Helbling, Arthur; Pichler, Werner J.
CS Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switz.
SO Journal of Investigational Allergology and Clinical Immunology (2001), 11(4), 275-284
CODEN: JIAIEF; ISSN: 1018-9068
PB Hogrefe & Huber Publishers
DT Journal
LA English
AB Recent data indicate that T cells play a major role in different forms of drug **allergies.** To show that T-cell reactions are involved in various forms of adverse reactions to different kinds of drugs, and that lymphocyte transformation and skin tests may be pos. in patients who had distinct clin. manifestations of drug **allergies.** We collected data of 44 patients with a highly suggestive history for adverse drug reaction who had on subsequent investigations a pos. lymphocyte transformation test. In 41/44 patients (93%) skin tests with the suspected drugs were performed and in some cases drug-specific **IgE** -antibodies were determined All patients were HLA typed. Clin. manifestations of the drug **allergy** were heterogeneous, comprising maculopapular and bullous exanthema, erythema exsudativum multiforme, vasculitis, serum sickness, **urticaria**, as well as involvement of internal organs. Maculopapular exanthemas formed the largest group (54%), followed by reactions more indicative of immediate hypersensitivity (28%), such as **urticaria**/angioedema. In most cases (63%), β-lactam antibiotics were found to have caused the **allergic** reaction. Skin tests for immediate reactions were pos. in 6/40 patients (15%) tested, those for late reactions in 24/38 patients (63%) tested. Our data provide evidence that drug-specific T cells can be detected in distinct clin. manifestations of drug **allergy.** A combined approach using a detailed case history, lymphocyte transformation tests, skin tests (immediate and delayed type) appears to be helpful to identifying the incriminated drug.
IT **103577-45-3**, Agopton
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T-cell reactions to drugs in distinct clin. manifestations of drug **allergy**)
RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:125206 CAPLUS
DN 137:210620
TI TU-572, a Potent and Selective CD45 Inhibitor, Suppresses **IgE**-Mediated **Anaphylaxis** and Murine Contact Hypersensitivity Reactions
AU Hamaguchi, Takuya; Takahashi, Akiko; Manaka, Akira; Sato, Masakazu; Osada, Hiroyuki
CS Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi, Japan
SO International Archives of Allergy and Immunology (2001), 126(4), 318-324
CODEN: IAAIEG; ISSN: 1018-2438
PB S. Karger AG
DT Journal
LA English
AB Background: CD45, receptor-type protein tyrosine phosphatases (PTPases) are essential components of signaling through both the T cell receptor and the B cell antigen receptor. However, the functional significance of CD45 in the signaling pathway through the high-affinity Ig (Ig) E receptor has not yet been established. In this study, we demonstrate that the potent CD45 inhibitor neg. regulates **IgE**-dependent **anaphylaxis** and contact hypersensitivity reactions. Method: We have previously found that TU-572, 2-[(4-methylthiopyridin-2-yl)methylsulfinyl]-5-isopropoxybenzimidazole, had a potent and selective inhibitory effect against PTPase activity of CD45. Using a CD45 inhibitor, we examined in vitro and in vivo **IgE**-mediated responses. Results: TU-572 potently inhibited histamine release from rat peritoneal mast cells and mouse systemic **anaphylaxis** reaction using monoclonal anti-dinitrophenyl (DNP) **IgE** and DNP-BSA. TU-572 also suppressed the immediate-type hypersensitivity response induced by repeated epicutaneous application of trinitrochlorobenzene in BALB/c mice. Conclusion: These findings revealed that the PTPase activity of CD45 played a critical role in signal transduction of **IgE**-mediated **anaphylaxis** in vitro and in vivo. PTPase inhibitors such as TU-572 are useful in the treatment of **allergic** diseases.
IT **326592-39-6**, TU 572
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TU-572, a potent and selective CD45 inhibitor, suppresses **IgE**-mediated **anaphylaxis** and murine contact hypersensitivity reactions)
RN 326592-39-6 CAPLUS
CN 1H-Benzimidazole, 5-(1-methylethoxy)-2-[[[4-(methylthio)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	145.98	307.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.65	-3.65

FILE 'STNGUIDE' ENTERED AT 11:22:08 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 2, 2005 (20050902/UP).

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	307.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.65

FILE 'CAPLUS' ENTERED AT 11:22:59 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 7 Sep 2005 VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L9 4437 L2

=> s wo2004041280/pn
L10 1 WO2004041280/PN
(WO2004041280/PN)

=> sel rn
E1 THROUGH E17 ASSIGNED

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         3.32     310.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -3.65

FILE 'REGISTRY' ENTERED AT 11:24:49 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     6 SEP 2005  HIGHEST RN 862534-94-9
DICTIONARY FILE UPDATES:    6 SEP 2005  HIGHEST RN 862534-94-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s e1-e17
             1 102625-70-7/BI
               (102625-70-7/RN)
             1 103577-45-3/BI
               (103577-45-3/RN)
             1 112-80-1/BI
               (112-80-1/RN)
             1 117976-89-3/BI
               (117976-89-3/RN)
             1 136565-26-9/BI
               (136565-26-9/RN)
             1 151499-39-7/BI
               (151499-39-7/RN)
             1 154-23-4/BI
               (154-23-4/RN)
             1 4091-50-3/BI
               (4091-50-3/RN)
             1 465-21-4/BI
               (465-21-4/RN)
             1 50-00-0/BI
               (50-00-0/RN)
```

```
              1 50-78-2/BI
                (50-78-2/RN)
              1 50678-27-8/BI
                (50678-27-8/RN)
              1 51-17-2/BI
                (51-17-2/RN)
              1 51-45-6/BI
                (51-45-6/RN)
              1 69365-65-7/BI
                (69365-65-7/RN)
              1 73590-58-6/BI
                (73590-58-6/RN)
              1 80890-47-7/BI
                (80890-47-7/RN)
L11          17 (102625-70-7/BI OR 103577-45-3/BI OR 112-80-1/BI OR 117976-89-3/
                BI OR 136565-26-9/BI OR 151499-39-7/BI OR 154-23-4/BI OR 4091-50
                -3/BI OR 465-21-4/BI OR 50-00-0/BI OR 50-78-2/BI OR 50678-27-8/B
                I OR 51-17-2/BI OR 51-45-6/BI OR 69365-65-7/BI OR 73590-58-6/BI
                OR 80890-47-7/BI)

=> d1-17
D1-17 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d 1-17

L11  ANSWER 1 OF 17  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   151499-39-7  REGISTRY
ED   Entered STN:  01 Dec 1993
CN   Bafilomycin (9CI)  (CA INDEX NAME)
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2,
       USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
               63 REFERENCES IN FILE CA (1907 TO DATE)
                2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
               63 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11  ANSWER 2 OF 17  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   136565-26-9  REGISTRY
ED   Entered STN:  04 Oct 1991
CN   9,11a-Methano-11aH-cyclohepta[a]naphthalen-8(9H)-one, 5-
     (benzoyloxy)dodecahydro-4-(hydroxymethyl)-4,9,11b-trimethyl-,
     (4R,4aR,5R,6aS,9S,11aS,11bS)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   9,11a-Methano-11aH-cyclohepta[a]naphthalen-8(9H)-one, 5-
     (benzoyloxy)dodecahydro-4-(hydroxymethyl)-4,9,11b-trimethyl-,
     [4R-(4α,4aα,5β,6aβ,9β,11aβ,11bβ)]-
OTHER NAMES:
CN   Scopadulciol
MF   C27 H36 O4
SR   CA
LC   STN Files:   ADISINSIGHT, AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, IPA,
       MEDLINE, TOXCENTER
         (*File contains numerically searchable property data)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **117976-89-3** REGISTRY
ED Entered STN: 16 Dec 1988
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[[[3-Methyl-4-(3-methoxypropoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CN 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CN 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]benzimidazole
CN LY 307640
CN Pariets
CN Rabeprazole
FS 3D CONCORD
MF C18 H21 N3 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

464 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
466 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **103577-45-3** REGISTRY
ED Entered STN: 02 Aug 1986
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-

pyridinyl]methyl]sulfinyl]-. (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (±)-Lansoprazole
CN 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CN A 65006
CN AG 1749
CN Agopton
CN Ilsatec
CN Ketian
CN Lancid
CN Lanfast
CN Lanproton
CN Lansopep
CN Lansophed
CN Lansoprazole
CN Lansox
CN Lanston
CN Lanz
CN Lanzol 30
CN Lanzopral
CN Lanzor
CN Lapraz
CN Ogast
CN Ogastro
CN PP/K-10
CN Prevacid
CN Promp
CN Prosogan
CN Suprecid
CN Takepron
CN Ulpax
CN Zoton
FS 3D CONCORD
DR 154727-72-7
MF C16 H14 F3 N3 O2 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1246 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1251 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **102625-70-7** REGISTRY

ED Entered STN: 14 Jun 1986
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
CN 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
CN BY 1023
CN Pantoprazole
CN Pantozol
CN SKF 96022
FS 3D CONCORD
DR 154644-14-1
MF C16 H15 F2 N3 O4 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

645 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
649 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **80890-47-7** REGISTRY
ED Entered STN: 16 Nov 1984
CN Oxacyclooctadeca-3,5,13,15-tetraen-2-one, 18-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-4-[[4-O-(aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1E)-1-propenyl-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-9-ethyl-8,10-dihydroxy-3,17-dimethoxy-5,7,11,13-tetramethyl-, (3Z,5E,7R,8R,9S,10S,11R,13E,15E,17S,18R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Concanamycin A
CN Oxacyclooctadecane, concanamycin A deriv.
OTHER NAMES:
CN Antibiotic X 4357B
CN Concanamycin
CN X 4357B
CN [7R-[3Z,5E,7R*,8R*,9S*,10S*,11R*,13E,15E,17S*,18R*[1S*,2R*,3S*[2R*,4R*,5S*,6R*(E)]]]-18-[3-[4-[[4-O-(Aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1-propenyl)-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-9-ethyl-8,10-dihydroxy-3,17-dimethoxy-5,7,11,13-tetramethyloxacyclooctadeca-3,5,13,15-tetraen-2-one

FS STEREOSEARCH
DR 66771-59-3
MF C46 H75 N O14
CI COM
LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

103 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
103 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **73590-58-6** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (±)-Omeprazole
CN 2-[[(3,5-Dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-5-methoxy-1H-benzimidazole

CN 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
CN Acidex
CN Antra
CN Antra MUPS
CN Audazol
CN Aulcer
CN Belmazol
CN Ceprandal
CN Desec
CN Dizprazol
CN Dudencer
CN Elgam
CN Emeproton
CN Epirazole
CN Gastrimut
CN GastroGard
CN Gastroloc
CN Gastrozole
CN Gibancer
CN H 168/68
CN Indurgan
CN Inhibitron
CN Inhipump
CN Logastric
CN Lomac
CN Losec
CN Mepral
CN Miol
CN Miracid
CN Mopral
CN Ocid
CN Omapren
CN Omebeta 20
CN Omed
CN Omedar
CN OMEP
CN Omepradex
CN Omepral
CN Omeprazen
CN Omeprazole
CN Omeprazon
CN Omepril
CN Omezol
CN Omezzol
CN Omid
CN Omisec
CN Omizac
CN OMP
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS 3D CONCORD
DR 172964-80-6, 131959-78-9
MF C17 H19 N3 O3 S
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3026 REFERENCES IN FILE CA (1907 TO DATE)
56 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3036 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **69365-65-7** REGISTRY
ED Entered STN: 16 Nov 1984
CN Piperidine, 4-(diphenylmethyl)-1-[(octylimino)methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Fenoctimin
CN Fenoctimine
FS 3D CONCORD
MF C27 H38 N2
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, DDFU, DRUGU, EMBASE, SYNTHLINE, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50678-27-8** REGISTRY
ED Entered STN: 16 Nov 1984
CN D-Glucopyranose, pentakis(3,4,5-trihydroxybenzoate) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN D-Glucose, pentagallate (7CI)
OTHER NAMES:
CN 1,2,3,4,6-Pentagalloyl-D-glucose
CN CJ 90002
CN D-Glucose, 1,2,3,4,6-pentagallate
CN Penta-O-galloyl-D-glucose
CN Pentagalloylglucose
FS STEREOSEARCH
DR 126420-90-4, 147370-08-9, 40410-94-4
MF C41 H32 O26
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, NAPRALERT, PHAR,

TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

99 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
99 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **4091-50-3** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzeneethanamine, 4-methoxy-N-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenethylamine, p-methoxy-N-methyl- (6CI, 8CI)
OTHER NAMES:
CN (p-Methoxyphenethyl)methylamine
CN 4-Methoxy-N-methylbenzeneethanamine
CN 4-Methoxy-N-methylphenethylamine
CN N-(p-Methoxyphenethyl)methylamine
CN N-Methyl-(p-methoxyphenethyl)amine
CN N-Methyl-β-(4-methoxyphenyl)ethylamine
CN N-Methyl-2-(4-methoxyphenyl)ethylamine
CN N-Methyl-4-methoxy-β-phenethylamine
CN N-Methyl-4-methoxyphenethylamine
CN N-Methyl-N-(4-methoxyphenethyl)amine
CN p-Methoxy-N-methylphenethylamine
CN [2-(4-Methoxyphenyl)ethyl]methylamine
FS 3D CONCORD

MF C10 H15 N O
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NAPRALERT, NIOSHTIC, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1151 REFERENCES IN FILE CA (1907 TO DATE)
745 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1151 REFERENCES IN FILE CAPLUS (1907 TO DATE)
15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **465-21-4** REGISTRY
ED Entered STN: 16 Nov 1984
CN Bufa-20,22-dienolide, 3,14-dihydroxy-, (3β,5β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5β-Bufa-20,22-dienolide, 3β,14-dihydroxy- (7CI, 8CI)
CN Bufalin (6CI)
OTHER NAMES:
CN NSC 89595
FS STEREOSEARCH
DR 2381-02-4
MF C24 H34 O4
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, PROMT, RTECS*, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

295 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
296 REFERENCES IN FILE CAPLUS (1907 TO DATE)
36 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **154-23-4** REGISTRY
ED Entered STN: 16 Nov 1984
CN 2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R,3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R-trans)-
CN Catechol (8CI)
OTHER NAMES:
CN (+)-(2R:3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
CN (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
CN (+)-Catechin
CN (+)-Catechol
CN (+)-Cianidanol
CN (+)-Cyanidan-3-ol
CN (+)-Cyanidanol
CN (+)-Cyanidanol-3
CN (2R,3S)-(+)-Catechin
CN 3-Cyanidanol, (+)-
CN Biocatechin
CN Catechin
CN Catechin (flavan)
CN Catechinic acid
CN Catechol (flavan)
CN Catechuic acid
CN Catergen
CN Cianidanol
CN Cyanidanol
CN Cyanidol
CN D-(+)-Catechin
CN D-Catechin
CN d-Catechin
CN D-Catechol
CN Dexcyanidanol
CN NSC 2819
CN Sunkatol No. 1

CN Teafuran 30A
CN trans-(+)-3,3',4',5,7-Flavanpentol
FS STEREOSEARCH
DR 523994-21-0, 321-01-7, 16198-00-8, 4211-28-3, 5323-80-8, 159761-73-6, 379227-23-3
MF C15 H14 O6
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6273 REFERENCES IN FILE CA (1907 TO DATE)
328 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6284 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **112-80-1** REGISTRY
ED Entered STN: 16 Nov 1984
CN 9-Octadecenoic acid (9Z)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9-Octadecenoic acid (Z)-
CN Oleic acid (8CI)
OTHER NAMES:
CN Δ9-cis-Octadecenoic acid
CN Δ9-cis-Oleic acid
CN 9-cis-Octadecenoic acid
CN 9-Octadecenoic acid, (Z)-
CN 9Z-Octadecenoic acid
CN cis-Δ9-Octadecenoic acid
CN cis-9-Octadecenoic acid
CN cis-Oleic acid
CN D 100
CN D 100 (fatty acid)
CN Edenor ATiO5
CN Edenor FTiO5
CN Emersol 205
CN Emersol 211
CN Emersol 213NF
CN Emersol 214NF

CN Emersol 233
CN Emersol 6313NF
CN Extra Oleic 80R
CN Extra Oleic 90
CN Extra Oleic 99
CN Extra Olein 80
CN Extra Olein 90R
CN Extraolein 90
CN Industrene 105
CN Lunac O-CA
CN Lunac O-LL
CN Lunac O-P
CN Lunac OA
CN NAA 35
CN Neo-Fat 92-04
CN Oleine 7503
CN Pamolyn 100
CN Priolene 6906
CN Priolene 6907
CN Priolene 6928
CN Priolene 6930
CN Priolene 6933
CN Vopcolene 27
CN Wecoline OO
CN Z-9-Octadecenoic acid
FS STEREOSEARCH
DR 8046-01-3, 56833-51-3, 17156-84-2
MF C18 H34 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

45296 REFERENCES IN FILE CA (1907 TO DATE)
2559 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
45372 REFERENCES IN FILE CAPLUS (1907 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **51-45-6** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole-4-ethanamine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Histamine (8CI)
OTHER NAMES:
CN β-Imidazolyl-4-ethylamine
CN 2-(1H-Imidazol-4-yl)ethanamine

CN 2-(1H-Imidazol-4-yl)ethylamine
CN 2-(1H-Imidazol-5-yl)ethanamine
CN 2-(1H-Imidazol-5-yl)ethylamine
CN 2-(4-Imidazolyl)ethanamine
CN 2-(4-Imidazolyl)ethylamine
CN 4-(2-Aminoethyl)imidazole
CN 5-Imidazoleethylamine
CN Eramin
CN Ergamine
CN Ergotidine
CN Imidazole-4-ethylamine
CN NSC 33792
FS 3D CONCORD
MF C5 H9 N3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

34678 REFERENCES IN FILE CA (1907 TO DATE)
479 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
34687 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **51-17-2** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Benzimidazole (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzimidazole (6CI, 8CI)
OTHER NAMES:
CN 1,3-Benzodiazole
CN 1,3-Diazaindene
CN 3-Azaindole
CN Azindole
CN Benziminazole
CN Benzoglyoxaline
CN Benzoimidazole
CN BZI
CN N,N'-Methenyl-o-phenylenediamine
CN NSC 759
CN o-Benzimidazole
FS 3D CONCORD
DR 25463-25-6, 79351-71-6, 116421-27-3
MF C7 H6 N2
CI COM, RPS
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,

CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6040 REFERENCES IN FILE CA (1907 TO DATE)
1881 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6047 REFERENCES IN FILE CAPLUS (1907 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50-78-2** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-(Acetyloxy)benzoic acid
CN 2-Acetoxybenzoic acid
CN 2-Carboxyphenyl acetate
CN A.S.A. Empirin
CN AC 5230
CN Acenterine
CN Acesal
CN Acesan
CN Acetard
CN Aceticyl
CN Acetilum acidulatum
CN Acetisal
CN Acetol
CN Acetonyl
CN Acetophen
CN Acetosal
CN Acetosalic acid
CN Acetosalin
CN Acetylin
CN Acetylsal
CN Acetylsalicylic acid
CN Acetyonyl
CN Acetysal
CN Acidum acetylsalicylicum
CN Acimetten
CN Acisal
CN Acylpyrin
CN Adiro
CN Albyl E
CN ASA
CN Asaflow
CN Asagran
CN Asatard
CN Ascoden 30
CN Ascolong
CN Ascriptin

CN Aspalon
CN Aspergum
CN Aspirdrops
CN Aspirin
CN Aspirin Protect 100
CN Aspirin Protect 300
CN Aspirin-Direkt
CN Aspirina 03
CN Aspro
CN Aspro Clear
CN Aspropharm
CN Asteric
CN Bayer
CN Benaspir
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS 3D CONCORD
DR 11126-35-5, 11126-37-7, 98201-60-6, 2349-94-2, 26914-13-6
MF C9 H8 O4
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19146 REFERENCES IN FILE CA (1907 TO DATE)
372 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
19191 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50-00-0** REGISTRY
ED Entered STN: 16 Nov 1984
CN Formaldehyde (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN BFV
CN F-gen
CN Fannoform
CN Floguard 1015
CN FM 282
CN Fordor
CN Formalin
CN Formalith
CN Formic aldehyde
CN Formol
CN Fyde
CN Lysoform
CN Methaldehyde

CN Methanal
CN Methyl aldehyde
CN Methylene oxide
CN Morbicid
CN NSC 298885
CN Oxomethane
CN Oxymethylene
CN Paraform
CN Superlysoform
FS 3D CONCORD
DR 8005-38-7, 8006-07-3, 8013-13-6, 112068-71-0
MF C H2 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, PS, RTECS*, SCISEARCH, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

$H_2C{=}O$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

68262 REFERENCES IN FILE CA (1907 TO DATE)
6511 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
68334 REFERENCES IN FILE CAPLUS (1907 TO DATE)
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	33.43	344.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.65

FILE 'CAPLUS' ENTERED AT 11:27:41 ON 07 SEP 2005

FILE COVERS 1907 - 7 Sep 2005 VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 117976-89-3/rn
           466 117976-89-3
            12 117976-89-3D
L12         457 117976-89-3/RN
                (117976-89-3 (NOTL) 117976-89-3D )

=> s 117976-89-3/rn or 103577-45-3/rn or 154644-14-1/rn or 172964-80-6/rn or
131959-78-9/rn
           466 117976-89-3
            12 117976-89-3D
           457 117976-89-3/RN
                (117976-89-3 (NOTL) 117976-89-3D )
          1251 103577-45-3
            17 103577-45-3D
          1241 103577-45-3/RN
                (103577-45-3 (NOTL) 103577-45-3D )
             0 154644-14-1
             0 154644-14-1D
             0 154644-14-1/RN
                (154644-14-1 (NOTL) 154644-14-1D )
             0 172964-80-6
             0 172964-80-6D
             0 172964-80-6/RN
                (172964-80-6 (NOTL) 172964-80-6D )
             0 131959-78-9
             0 131959-78-9D
             0 131959-78-9/RN
                (131959-78-9 (NOTL) 131959-78-9D )
L13         1434 117976-89-3/RN OR 103577-45-3/RN OR 154644-14-1/RN OR 172964-80-
                 6/RN OR 131959-78-9/RN

=> s l13 and l7
L14            1 L13 AND L7

=> d bib abs hitstr

L14  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:412815  CAPLUS
DN   140:386032
TI   Composition using a benzimidazolic compound with proton pump inhibitor
     activity for preventing secretion of immunoglobulin E-dependent histamine
     releasing factor
IN   Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA   S. Korea
SO   PCT Int. Appl., 29 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   WO 2004041280         A1    20040521    WO 2003-KR2332           20031103
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
             TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
```

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI KR 2002-67653 A 20021102
KR 2003-75511 A 20031028

AB The invention discloses a composition for inhibiting the secretion of an **IgE**-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, **oleic acid**, **catechin**, **scopadulciol**, **pentagalloyl** glucose, **bufalin**, and macrolide antibiotic **bafilomycin** and **concanamycin**, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various **allergic** diseases and **malaria**, which are caused by the **IgE**-dependent histamine-releasing factor.

IT **73590-58-6**, Omeprazole **102625-70-7**, Pantoprazole **103577-45-3**, Lansoprazole **117976-89-3**, Rabeprazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazolic compound with proton pump inhibitor activity for preventing secretion of **IgE**-dependent histamine releasing factor)

RN 73590-58-6 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



=> s l13 adn l8
MISSING OPERATOR L13 ADN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l13 and l8
L15 2 L13 AND L8

=> d 1-2 bib abs hitstr

L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	KR 2002-67653	A	20021102		
	KR 2003-75511	A	20031028		

AB The invention discloses a composition for inhibiting the secretion of an **IgE**-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various **allergic**

diseases and **malaria**, which are caused by the **IgE** -dependent histamine-releasing factor.

IT **73590-58-6**, Omeprazole **102625-70-7**, Pantoprazole **103577-45-3**, Lansoprazole **117976-89-3**, Rabeprazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazolic compound with proton pump inhibitor activity for preventing secretion of **IgE**-dependent histamine releasing factor)

RN 73590-58-6 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:223222 CAPLUS

DN 137:257592
TI T-cell reactions to drugs in distinct clinical manifestations of drug **allergy**
AU Neukomm, Corinne B.; Yawalkar, Nikhil; Helbling, Arthur; Pichler, Werner J.
CS Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switz.
SO Journal of Investigational Allergology and Clinical Immunology (2001), 11(4), 275-284
CODEN: JIAIEF; ISSN: 1018-9068
PB Hogrefe & Huber Publishers
DT Journal
LA English
AB Recent data indicate that T cells play a major role in different forms of drug **allergies.** To show that T-cell reactions are involved in various forms of adverse reactions to different kinds of drugs, and that lymphocyte transformation and skin tests may be pos. in patients who had distinct clin. manifestations of drug **allergies.** We collected data of 44 patients with a highly suggestive history for adverse drug reaction who had on subsequent investigations a pos. lymphocyte transformation test. In 41/44 patients (93%) skin tests with the suspected drugs were performed and in some cases drug-specific **IgE** -antibodies were determined All patients were HLA typed. Clin. manifestations of the drug **allergy** were heterogeneous, comprising maculopapular and bullous exanthema, erythema exsudativum multiforme, vasculitis, serum sickness, **urticaria**, as well as involvement of internal organs. Maculopapular exanthemas formed the largest group (54%), followed by reactions more indicative of immediate hypersensitivity (28%), such as **urticaria**/angioedema. In most cases (63%), β-lactam antibiotics were found to have caused the **allergic** reaction. Skin tests for immediate reactions were pos. in 6/40 patients (15%) tested, those for late reactions in 24/38 patients (63%) tested. Our data provide evidence that drug-specific T cells can be detected in distinct clin. manifestations of drug **allergy.** A combined approach using a detailed case history, lymphocyte transformation tests, skin tests (immediate and delayed type) appears to be helpful to identifying the incriminated drug.
IT **103577-45-3**, Agopton
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T-cell reactions to drugs in distinct clin. manifestations of drug **allergy**)
RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (l13 or l3) and l7
L16 1 (L13 OR L3) AND L7

=> d bib

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004041280	A1	20040521	WO 2003-KR2332	20031103

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI KR 2002-67653	A	20021102	
KR 2003-75511	A	20031028	

=> s (l13 or l3) and l8
L17 4 (L13 OR L3) AND L8

=> d 1-4 bib abs hitstr

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:834661 CAPLUS
DN 142:348646
TI Recurrent **anaphylaxis** linked to pantoprazole
AU Kollmeier, Alexa P.; Eddleston, Jane; Zuraw, Bruce L.; Christiansen, Sandra C.
CS Department of Asthma, Allergy and Immunol., Scripps Clin., La Jolla, CA, 92037, USA
SO Journal of Allergy and Clinical Immunology (2004), 114(4), 975-977
CODEN: JACIBY; ISSN: 0091-6749
PB Elsevier Inc.
DT Journal
LA English
AB The case of a 47-yr-old man with recurrent **anaphylaxis** induced by pantoprazole, a benzimidazole proton pump inhibitor, is presented. In this patient, the pos. skin test response and increased tryptase level are consistent with prior case reports of proton pump inhibitor **anaphylaxis** and suggest an immediate hypersensitivity mechanism. Although mutations in the CYP2C19 gene were not identified, the timing of anaphylactic events invokes the possible involvement of modifying pharmacogenetic factors, variations in relative levels of drug-specific **IgE**, or both.
IT **102625-70-7**, Pantoprazole **138786-67-1**, Protonix
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(recurrent **anaphylaxis** linked to pantoprazole)
RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 138786-67-1 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	KR 2002-67653	A	20021102		
	KR 2003-75511	A	20031028		

AB The invention discloses a composition for inhibiting the secretion of an **IgE**-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient.

The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various **allergic** diseases and **malaria**, which are caused by the **IgE** -dependent histamine-releasing factor.

IT **73590-58-6**, Omeprazole **102625-70-7**, Pantoprazole **103577-45-3**, Lansoprazole **117976-89-3**, Rabeprazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazolic compound with proton pump inhibitor activity for preventing secretion of **IgE**-dependent histamine releasing factor)

RN 73590-58-6 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:223222 CAPLUS
DN 137:257592
TI T-cell reactions to drugs in distinct clinical manifestations of drug **allergy**
AU Neukomm, Corinne B.; Yawalkar, Nikhil; Helbling, Arthur; Pichler, Werner J.
CS Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switz.
SO Journal of Investigational Allergology and Clinical Immunology (2001), 11(4), 275-284
CODEN: JIAIEF; ISSN: 1018-9068
PB Hogrefe & Huber Publishers
DT Journal
LA English
AB Recent data indicate that T cells play a major role in different forms of drug **allergies.** To show that T-cell reactions are involved in various forms of adverse reactions to different kinds of drugs, and that lymphocyte transformation and skin tests may be pos. in patients who had distinct clin. manifestations of drug **allergies.** We collected data of 44 patients with a highly suggestive history for adverse drug reaction who had on subsequent investigations a pos. lymphocyte transformation test. In 41/44 patients (93%) skin tests with the suspected drugs were performed and in some cases drug-specific **IgE** -antibodies were determined All patients were HLA typed. Clin. manifestations of the drug **allergy** were heterogeneous, comprising maculopapular and bullous exanthema, erythema exsudativum multiforme, vasculitis, serum sickness, **urticaria**, as well as involvement of internal organs. Maculopapular exanthemas formed the largest group (54%), followed by reactions more indicative of immediate hypersensitivity (28%), such as **urticaria**/angioedema. In most cases (63%), β-lactam antibiotics were found to have caused the **allergic** reaction. Skin tests for immediate reactions were pos. in 6/40 patients (15%) tested, those for late reactions in 24/38 patients (63%) tested. Our data provide evidence that drug-specific T cells can be detected in distinct clin. manifestations of drug **allergy.** A combined approach using a detailed case history, lymphocyte transformation tests, skin tests (immediate and delayed type) appears to be helpful to identifying the incriminated drug.
IT **103577-45-3**, Agopton
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T-cell reactions to drugs in distinct clin. manifestations of drug **allergy**)
RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:125206 CAPLUS
DN 137:210620
TI TU-572, a Potent and Selective CD45 Inhibitor, Suppresses **IgE** -Mediated **Anaphylaxis** and Murine Contact Hypersensitivity

Reactions
AU Hamaguchi, Takuya; Takahashi, Akiko; Manaka, Akira; Sato, Masakazu; Osada, Hiroyuki
CS Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi, Japan
SO International Archives of Allergy and Immunology (2001), 126(4), 318-324
CODEN: IAAIEG; ISSN: 1018-2438
PB S. Karger AG
DT Journal
LA English
AB Background: CD45, receptor-type protein tyrosine phosphatases (PTPases) are essential components of signaling through both the T cell receptor and the B cell antigen receptor. However, the functional significance of CD45 in the signaling pathway through the high-affinity Ig (Ig) E receptor has not yet been established. In this study, we demonstrate that the potent CD45 inhibitor neg. regulates **IgE**-dependent **anaphylaxis** and contact hypersensitivity reactions. Method: We have previously found that TU-572, 2-[(4-methylthiopyridin-2-yl)methylsulfinyl]-5-isopropoxybenzimidazole, had a potent and selective inhibitory effect against PTPase activity of CD45. Using a CD45 inhibitor, we examined in vitro and in vivo **IgE**-mediated responses. Results: TU-572 potently inhibited histamine release from rat peritoneal mast cells and mouse systemic **anaphylaxis** reaction using monoclonal anti-dinitrophenyl (DNP) **IgE** and DNP-BSA. TU-572 also suppressed the immediate-type hypersensitivity response induced by repeated epicutaneous application of trinitrochlorobenzene in BALB/c mice. Conclusion: These findings revealed that the PTPase activity of CD45 played a critical role in signal transduction of **IgE**-mediated **anaphylaxis** in vitro and in vivo. PTPase inhibitors such as TU-572 are useful in the treatment of **allergic** diseases.
IT **326592-39-6**, TU 572
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TU-572, a potent and selective CD45 inhibitor, suppresses **IgE**-mediated **anaphylaxis** and murine contact hypersensitivity reactions)
RN 326592-39-6 CAPLUS
CN 1H-Benzimidazole, 5-(1-methylethoxy)-2-[[[4-(methylthio)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

```
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                   61.96      406.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                   -5.11       -8.76

STN INTERNATIONAL LOGOFF AT 11:32:39 ON 07 SEP 2005


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptamxg1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  DEC 23  New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                  USPAT2
 NEWS  4  JAN 13  IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS  5  JAN 13  New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                  INPADOC
 NEWS  6  JAN 17  Pre-1988 INPI data added to MARPAT
 NEWS  7  JAN 17  IPC 8 in the WPI family of databases including WPIFV
 NEWS  8  JAN 30  Saved answer limit increased
 NEWS  9  FEB 21  STN AnaVist, Version 1.1, lets you share your STN AnaVist
                  visualization results
 NEWS 10  FEB 22  The IPC thesaurus added to additional patent databases on STN
 NEWS 11  FEB 22  Updates in EPFULL; IPC 8 enhancements added
 NEWS 12  FEB 27  New STN AnaVist pricing effective March 1, 2006
 NEWS 13  FEB 28  MEDLINE/LMEDLINE reload improves functionality
 NEWS 14  FEB 28  TOXCENTER reloaded with enhancements
 NEWS 15  FEB 28  REGISTRY/ZREGISTRY enhanced with more experimental spectral
                  property data
 NEWS 16  MAR 01  INSPEC reloaded and enhanced
 NEWS 17  MAR 03  Updates in PATDPA; addition of IPC 8 data without attributes
 NEWS 18  MAR 08  X.25 communication option no longer available after June 2006
 NEWS 19  MAR 22  EMBASE is now updated on a daily basis
 NEWS 20  APR 03  New IPC 8 fields and IPC thesaurus added to PATDPAFULL
 NEWS 21  APR 03  Bibliographic data updates resume; new IPC 8 fields and IPC
                  thesaurus added in PCTFULL
 NEWS 22  APR 04  STN AnaVist $500 visualization usage credit offered
 NEWS 23  APR 12  LINSPEC, learning database for INSPEC, reloaded and enhanced
 NEWS 24  APR 12  Improved structure highlighting in FQHIT and QHIT display
                  in MARPAT
 NEWS 25  APR 12  Derwent World Patents Index to be reloaded and enhanced during
                  second quarter; strategies may be affected

 NEWS EXPRESS  FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
               http://download.cas.org/express/v8.0-Discover/
```

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:41:52 ON 14 APR 2006

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:42:16 ON 14 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 APR 2006  HIGHEST RN 880252-04-0
DICTIONARY FILE UPDATES:  12 APR 2006  HIGHEST RN 880252-04-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s 326592-39-6/rn
L1            1 326592-39-6/RN

=> d
```

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN **326592-39-6** REGISTRY
ED Entered STN: 11 Mar 2001
CN 1H-Benzimidazole, 5-(1-methylethoxy)-2-[[[4-(methylthio)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN TU 572
FS 3D CONCORD
MF C17 H19 N3 O2 S2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, PROUSDDR, SYNTHLINE



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s omeprazole
L2 23 OMEPRAZOLE

=> d

L2 ANSWER 1 OF 23 REGISTRY COPYRIGHT 2006 ACS on STN
RN 755036-61-4 REGISTRY
ED Entered STN: 01 Oct 2004
CN 1H-Benzimidazole, 5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, hydrate (2:3) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **S-Omeprazole sesquihydrate**
FS STEREOSEARCH
MF C17 H19 N3 O3 S . 3/2 H2 O
SR CA
LC STN Files: CA, CAPLUS
CRN (119141-88-7)

Absolute stereochemistry. Rotation (-).



●3/2 H_2O

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s lansoprazole
L3 18 LANSOPRAZOLE

=> d

L3 ANSWER 1 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN
RN 482370-08-1 REGISTRY
ED Entered STN: 28 Jan 2003
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-, mixt. with 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Lansoprazole-amoxicillin mixt.**
FS STEREOSEARCH
MF C16 H19 N3 O5 S . C16 H14 F3 N3 O2 S
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 103577-45-3
CMF C16 H14 F3 N3 O2 S



CM 2

CRN 26787-78-0
CMF C16 H19 N3 O5 S

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s pantoprazole
L4 26 PANTOPRAZOLE

=> d

L4 ANSWER 1 OF 26 REGISTRY COPYRIGHT 2006 ACS on STN
RN 867300-65-0 REGISTRY
ED Entered STN: 11 Nov 2005

CN 1H-Benzimidazol-5-ol, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **6-Hydroxy-pantoprazole thioether**
FS 3D CONCORD
MF C16 H15 F2 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s rabeprazole
L5 6 RABEPRAZOLE

=> d

L5 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 226904-99-0 REGISTRY
ED Entered STN: 01 Jul 1999
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, calcium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Rabeprazole calcium**
DR 858585-57-6
MF C18 H21 N3 O3 S . 1/2 Ca
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS
CRN (117976-89-3)



●1/2 Ca

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.74	30.95

STN INTERNATIONAL LOGOFF AT 10:45:16 ON 14 APR 2006